"Guidelines for the Treatment of Preoperative Anaemia with Epoetin."

According to the author's abstract of an article published in Biodrugs, "Recombinant human erythropoietin (epoetin) has been approved for use in patients undergoing autologous blood donation (ABD) in Japan, the European Union, and Canada since 1993, 1994, and 1996, respectively, and for perisurgical adjuvant therapy without ABD in Canada and the U.S. since 1996. Early clinical trials of epoetin therapy in the setting of ABD have provided important information with respect to clinical safety, dose, and erythropoietic response. Later trials of perisurgical epoetin therapy without ABD provided data on efficacy (i.e., reduced allogeneic blood exposure) that led to approval of epoetin in this...

Want to see the full article?

• Purchase this article for only $3.00